Inactive Instrument

Highlights EXOPHARM

Equities

EX1

AU0000030975

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

Tryp Therapeutics Inc. completed the acquisition of Exopharm Limited in a reverse merger transaction.	04-30	CI
Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-26	CI
Exopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2023	28/08/23	CI
Exopharm Limited Announces Executive Changes	22/06/23	CI
Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2022	26/02/23	CI
Exopharm Limited Announces Board Changes	22/02/23	CI
Sartorius BIA Separations and Exopharm Ltd Testing the Synergy of Exopharm's Patented LEAP Technology Together with Bia's Unique Cim (Convective Interaction Media) Monolith Chromatography for Improved Large- Scale Exosome Production and Commercialization	16/11/22	CI
Exopharm Limited Will Commence LEAP Technology Transfer to AIRM under MSA	13/11/22	CI
Exopharm Receives $2.6 Million R&D Tax Rebate	27/10/22	MT
Exopharm Limited Announces Study Results Indicate Exosomes Safe for Clinical Pursuit	27/09/22	CI
Exopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2022	30/08/22	CI
Exopharm Limited Reports Earnings Results for the Half Year Ended December 31, 2021	25/02/22	CI
Exopharm Limited Signs Master Collaborative Services Agreement with the Astellas Institute for Regenerative Medicine	30/01/22	CI
Exopharm Gets US Patent for Drug Delivery Technology	22/12/21	MT
Exopharm Limited Announces Further Step Towards Granted US Patent for its LEAP Technology	26/09/21	CI
Exopharm Limited Reaches Agreement to Conduct A Research Collaboration with Showa Denko Materials Co., Ltd	08/09/21	CI
Exopharm : Widens After-Tax Loss in FY21; Shares Jump 6%	30/08/21	MT
Exopharm Limited Reports Earnings Results for the Full Year Ended June 30, 2021	29/08/21	CI
Exopharm Limited Signs Non-Binding Heads of Agreement with the Finnish Red Cross Blood Service	05/04/21	CI
Exopharm Limited Announces Positive PLEXOVAL II Phase 1 Clinical Trial Results with Off-the- Shelf PlexarisTM	05/04/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights EXOPHARM

Equities

EX1

AU0000030975

Highlights

Filters